TCM
泰宗生物科技股份有限公司
TCM is a Taiwan TWSE-listed biotechnology company; its most advanced asset is U101 (Phase 3; recruiting, Recurrent Urinary Tract Infections in Women), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| U101 | — | Phase 3; recruiting | Recurrent Urinary Tract Infections in Women | Taiwan | 2026-10-02 | Trial registry |
| PTX-9908 | — | Phase 1 / Phase 2; withdrawn | Carcinoma, Hepatocellular | Taiwan | 2026-10-02 | Trial registry |
| TCM-700C | — | Phase 3; withdrawn | Chronic Hepatitis C | China, Taiwan | 2017-04-28 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.